BeStock  
Stocks › BEAM

Beam Therapeutics BEAM

US equityMarket cap rank #2581AI medical concept stocksGene Editing
$25.67 +$1.17 (+4.78%)
Pre-market · Oct 6, 7:30 am ET · After hours $25.55 -0.47%
Open$24.48
Prev close$24.50
Day range$23.83 – $26.04
Volume2.00M
Market cap$2.65B
P/E (TTM)–
Dividend yield–

BEAM Stock News

Headlines matching Beam Therapeutics or the BEAM ticker, most recent first.

  • JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35Market news · 9 Sep 2026
  • A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80Market news · 9 Sep 2026
  • H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80Market news · 9 Sep 2026
  • Shimizu has added a 1.5-hour fire-resistant specification to its Hi-Wood Beam product lineup.Shimizu · 3 Sep 2026
  • J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $44Market news · 7 Aug 2026
  • A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $43 to $78Market news · 6 Aug 2026
  • A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $78Market news · 5 Aug 2026
  • Freedom Capital Markets Downgrades Beam Global(BEEM.US) to Hold Rating, Maintains Target Price $1.5Market news · 26 Aug 2026
  • Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Cuts Target Price to $3Market news · 22 Aug 2026
  • BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47Market news · 9 Jul 2026
  • HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price TargetBenzinga · 7 Jul 2026
  • 4: Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.SEC · 2 Jul 2026
  • Freedom Capital Markets Initiates Beam Global(BEEM.US) With Buy Rating, Announces Target Price $1.5Market news · 18 Jul 2026
  • Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70Market news · 4 Jun 2026
  • Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65Market news · 23 Jun 2026

Discussion

No comments yet — be the first to weigh in on BEAM.

Leave a comment

Scroll to Top